Home / Going-concern warnings / Olema Pharmaceuticals, Inc.
Filed 2026-05-12 路 Form 10-Q 路 Accession 0001193125-26-218156 small
Price before filing: $14.86 (2026-05-11 close, split/dividend-adjusted)
Market cap at flag: $1.44B (2026-05-12) 路 Latest: $687.3M (2026-10-16)
| Window | OLMA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -34.4% | -0.2% | -34.2% | 2026-06-11 |
| 90 days | -19.7% | +4.8% | -24.5% | 2026-08-10 |
| 180 days | pending | pending | until 2026-11-08 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.